TIDMFDBK
RNS Number : 6399I
Feedback PLC
12 August 2019
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014. Upon the
publication of this announcement via Regulatory Information
Service, this inside information is now considered to be in the
public domain
Feedback plc
Proposed placing and subscription to raise GBP2 million,
proposed grant of options, proposed amendment to Share Option
Scheme and notice of General Meeting
Cambridge, 12 August 2019: Feedback plc (AIM: FDBK, "Feedback"
or the "Company"), the specialist medical imaging technology
company, announces that it has conditionally raised a total of GBP2
million (before expenses) via a proposed placing by Peterhouse
Capital Limited and Stanford Capital Partners Limited, and a
subscription of a total of 166,666,667 new ordinary shares in the
Company ("New Ordinary Shares"), at an issue price of 1.2 pence per
New Ordinary Share (the "Issue Price"), (the "Fundraise"). The
Fundraise is subject to, inter alia, the approval of shareholders
at a general meeting of the Company.
Fundraise Highlights:
-- The Company has conditionally raised GBP2 million (before
expenses) through the issue of the 166,666,667 New Ordinary
Shares.
-- The Placing and the Subscription are subject to, inter alia,
shareholder approval at a general meeting of the Company on 29
August 2019. If approved, the New Ordinary Shares are expected to
be admitted to on AIM on 30 August 2019.
-- The Placing Price represents a discount of approximately
14.3% to the closing mid-market price of 1.4 pence per Ordinary
Share on 9 August 2019.
-- The net proceeds of the Placing and the Subscription will be used:
o To complete the development of the Bleepa(TM) , the Company's
clinical messaging product;
o To build a Sales/support team to market and onboard users onto
the Bleepa(TM) product; and
o For general working capital.
-- The New Ordinary Shares will represent 30.78% of the issued
share capital of the Company as enlarged by the Fundraise.
Dr Alastair Riddell, Non-Executive Chairman of Feedback
said:
"I am delighted with the support shown by new and existing
shareholders for our new product Bleepa(TM) . This is an evolution
from Cadran devised and driven by the creativity of our CEO, Tom
Oakley, and developed with the assistance of our partners Future
Processing. We believe Bleepa(TM) is set to transform the outlook
for the Company and could change the way medical images are
communicated in everyday clinical practice on mobile devices and
laptops."
Proposed Grant of Options and amendment to EMI Option Scheme
The Board believes that it is very important to incentivise key
members of the management team. In conjunction with the Fundraise,
the Board therefore intends to grant Tom Oakley, CEO of Feedback,
options over new ordinary shares in the Company, representing
approximately 2.5 per cent. of the Company's issued share capital
as enlarged by the Fundraise. The grant of options will be subject
to shareholder approval at the General Meeting and, if approved,
will be granted pursuant to the Company's EMI Option Scheme.
The EMI Option Scheme currently contains a limit on the number
of options that can be granted in a 10-year period of 10 per cent.
of the issued share capital at the time of grant. Including the
proposed grant of options to Tom Oakley mentioned above, a total of
9.97 per cent. of the Enlarged Share Capital will have been granted
under option in the last 10-year period, of which 2.26 per cent.
was issued in the period but subsequently lapsed or were exercised.
Accordingly, subject to shareholder approval at the General
Meeting, the Board intends to amend its EMI Option Scheme to
increase the number of options that can be granted during the
10-year period from 10 per cent. to 12.5 per cent of the Company's
issued share capital at the time of the grant.
Notice of General Meeting and Shareholder Circular
The Fundraise is conditional, inter alia, on the approval of
shareholders of resolutions to be proposed at a general meeting of
the Company to provide authority to the Directors to allot further
new ordinary shares otherwise than on a pre-emptive basis.
A General Meeting of the Company will be held at the offices of
Peterhouse Capital Limited, 80 Cheapside, London EC2V 6EE 1:00 p.m.
on 29 August 2019, to seek this shareholder approval. A Circular
containing a Notice of General Meeting will be posted to
shareholders on or around 13 August 2019 and will be available on
the Company's website, www.fbkmed.com, shortly thereafter.
The above summary should be read in conjunction with the full
text of this announcement.
1. Introduction
The Company is pleased to announce that it has conditionally
raised GBP2 million (before expenses), by way of the proposed
placing and the proposed subscription, a total of 166,666,667 New
Ordinary Shares at the issue price of 1.2 pence per New Ordinary
Share. The net proceeds of the Placing and the Subscription will be
used predominantly to initiate the roll out of Bleepa(TM) , the
Company's clinical messaging product. As previously announced,
Feedback plans to establish a leading role in the medical
communication market. Bleepa(TM) , is currently in beta development
and will be formally launched at NHS Expo on 4-5 September 2019 in
Manchester.
The Placing and the Subscription are subject to, inter alia, the
approval of Shareholders at the General Meeting. Peterhouse and
Stanford Capital are acting as joint brokers in relation to the
Placing.
Admission of the New Ordinary Shares is expected to take place
at 8:00 a.m. on 30 August 2019, should the Resolutions, further
details of which can be found below, be passed at the General
Meeting.
2. Background to and reasons for the Placing and the Subscription
Recent strategic review and trading update
On 10 July 2019, Feedback announced an update on its trading for
the year ended 31 May 2019. Amongst other things, this update
reported that Feedback had generated unaudited revenue of GBP563k
which represented an increase of approximately 23 per cent. on the
previous financial year (year to 31 May 2018: GBP458k).
The Company also announced the result of its strategic review of
the Cadran portfolio.
Cadran is Feedback's established Picture Archiving and
Communications System (PACS) which facilitates the review of
medical imaging studies by clinicians. It is a progressive and
rigorously tested Class 1 medical device with a longstanding legacy
of service at NHS institutions, such as the Royal Papworth
Hospital. However, it is currently positioned in a competitive
market that shows little opportunity for future growth.
According to BMJ Innovations, 97% of hospital doctors routinely
use WhatsApp to communicate about patients. There is an increasing
trend for clinicians to use personal devices to discuss patient
care and make clinical decisions, as it is more convenient and
efficient than traditional methods of clinical communication.
Medical images are often shared as part of these chats as photos of
computer screens, and do not meet diagnostic clinical standards.
This raises a number of concerns with regard to safety of patient
data, breaches of GDPR and the ability to make safe clinical
decisions without using clinical grade medical images.
By incorporating a dedicated, encrypted messaging function to
Feedback's existing Cadran technology, the Directors believe it can
become a medical communication device capable of sharing clinical
grade medical imaging directly from a hospital PACS to mobile
devices, ensuring the safe handling of patient data and
facilitating a secure means of communication for clinicians. It is
estimated that there are between 10 million and 15 million doctors
globally. In the UK, across NHS hospital, community and primary
care settings, there are approximately 150,000 doctors in total and
over 320,000 nurses and midwives.
Any hospital that uses Bleepa(TM) will own the chat data and the
entire chat is intended to be exportable into the electronic
patient record upon the patient being discharged. The Directors
believe Bleepa(TM) will be one of a limited number of communication
devices capable of displaying medical images and CE marked as a
medical device.
Having undertaken a period of market research alongside NHS
clinicians, the Company has decided to invest in the product
enhancement of Cadran and launch the new product, Bleepa(TM) , at
NHS Expo on 4-5 September 2019 in Manchester. It is proposed to
market Bleepa(TM) using a SaaS model and charging in the order of
GBP10 per month per user, with a 12-month minimum contract and a 3
month cancellation period.
The Company believes that there may be further opportunities for
the use of Bleepa(TM) outside the UK, both within the EU and in
non-GDPR markets such as India and China.
As previously announced, the Board will continue its review of
the TexRAD product portfolio. The Company intends to issue regular
updates to the market on the progress of both the TexRAD review and
new product opportunities.
3. Reasons for the Placing and use of proceeds
Pursuant to the Placing and the Subscription, the Company will
receive net proceeds of approximately GBP1.9 million. The net
Placing and Subscription funds will be used for the following
purposes:
-- To complete the development of the Bleepa(TM) product;
-- To build a Sales/support team to market and onboard users onto the Bleepa(TM) product; and
-- For general working capital.
4. Details of the Placing, the Subscription and Admission
The Company has conditionally raised GBP2 million (before
expenses), representing the issue of 166,666,667 New Ordinary
Shares at the Issue Price, by way of the Placing and the
Subscription. The Issue Price of 1.2 pence represents a discount of
14.3 per cent. to the closing middle market price of an Ordinary
Share on 9 August 2019, being the latest practicable date prior to
the announcement of the Placing and the Subscription.
The Placing and the Subscription are conditional, inter alia,
upon:
-- the passing of the Resolutions without amendment at the General Meeting;
-- admission of the New Ordinary Shares to trading on AIM
becoming effective by not later than 8.00 a.m. on 30 August 2019
(or such later time and/or date (not being later than 31 October
2019) as Peterhouse, Stanford Capital and the Company may
agree).
In addition to the above, the Placing and the Subscription are
inter-conditional, and the Placing is conditional upon the Placing
Agreement (as described in more detail below) becoming
unconditional in all respects and not having been terminated in
accordance with its terms.
The Placing and the Subscription will result in the issue of a
total of 166,666,667 New Ordinary Shares, representing, in
aggregate, approximately 30.87 per cent. of the Enlarged Share
Capital. Such New Ordinary Shares, when issued and fully paid, will
rank pari passu in all respects with the Existing Ordinary Shares
and therefore will rank equally for all dividends or other
distributions declared, made or paid after the relevant date of
Admission.
Application will be made to the London Stock Exchange for the
New Ordinary Shares to be admitted to trading on AIM and,
conditional, inter alia, on the approval of Shareholders at the
General Meeting, admission of the New Ordinary Shares is expected
to occur on 30 August 2019.
It is expected that CREST accounts will be credited on the day
of Admission as regards the New Ordinary Shares in uncertificated
form and that certificates for those shares to be issued in
certificated form will be dispatched by first class post by 13
September 2019.
5. The Placing
Pursuant to the terms of the Placing Agreement, Peterhouse and
Stanford Capital, as agents for the Company, have agreed
conditionally to use their reasonable endeavours to procure
subscribers for the Placing Shares at the Issue Price. The Placing
is not being underwritten.
The obligations of Peterhouse and Stanford Capital under the
Placing Agreement are conditional, among other things, upon: (i)
the passing of the Resolutions without amendment at the General
Meeting; and (ii) Admission becoming effective by not later than
8.00 a.m. on 30 August 2019 (or such later time and/or date (not
being later than 31 October 2019) as Peterhouse, Stanford Capital
and the Company may agree).
The Placing Agreement contains certain warranties and
indemnities given by the Company in favour of Peterhouse and
Stanford Capital as to certain matters relating to the Company's
group and its business. The obligations of Peterhouse and Stanford
Capital under the Placing Agreement may be terminated in certain
circumstances if there occurs either a breach of any of the
warranties or if a materially adverse event occurs at any time
prior to Admission. If the conditions in the Placing Agreement are
not fulfilled on or before the relevant date in the Placing
Agreement or, if applicable, waived, then the relevant placing
monies will be returned to subscribers for New Ordinary Shares
without interest at their own risk.
The Placing Agreement also provides for the Company to pay
Peterhouse and Stanford Capital commissions and certain other costs
and expenses incidental to the Placing and Admission.
6. The Subscription
The Company has received letters of subscription for, in
aggregate, 57,700,000 Subscription Shares. The Subscription is
conditional, among other things, upon: (i) the passing of the
Resolutions without amendment at the General Meeting; and (ii)
Admission becoming effective by not later than 8.00 a.m. on 30
August 2019 (or such later time and/or date (not being later than
31 October 2019) as the Company and Brokers may agree).
7. Significant shareholder and Director subscriptions
Details of the subscriptions by Directors and persons
discharging managerial responsibilities in the Subscription at the
Issue Price and their resultant shareholdings on Admission are as
follows:
Name New Ordinary Ordinary Shares Percentage held
Shares being on Admission of Enlarged
subscribed Share Capital
on Admission
Lindsay Melvin (Director) 416,667 1,016,667 0.19
Prof Rory Shaw (PDMR) 4,166,667 4,166,667 0.77
The subscriptions by Lindsay Melvin and Prof Rory Shaw in the
Subscription are, in aggregate, deemed to be related party
transactions pursuant to rule 13 of the AIM Rules for Companies.
Accordingly, the Independent Directors consider, having consulted
with the Company's nominated adviser, Allenby Capital, that the
terms of subscription by Lindsay Melvin and Prof Rory Shaw are fair
and reasonable insofar as Shareholders are concerned.
Thomas Charlton, a substantial shareholder of the Company,
having an interest in approximately 23.25 per cent. of the Existing
Ordinary Shares, is subscribing for 33,200,000 New Ordinary Shares,
which represents an aggregate amount of GBP398,400 at the Issue
Price, pursuant to the Subscription. Tom Charlton's participation
in the Subscription constitutes a related party transaction under
rule 13 of the AIM Rules. Accordingly, the Independent Directors
consider, having consulted with the Company's nominated adviser,
Allenby Capital, that the terms of subscription for the New
Ordinary Shares by Tom Charlton are fair and reasonable insofar as
Shareholders are concerned.
8. Proposed Grant of Options and amendment to EMI Option Scheme
The Board believes that it is very important to incentivise key
members of the management team. In conjunction with the Fundraise,
the Board therefore intends to grant Tom Oakley, CEO of Feedback,
options over new ordinary shares in the Company ("Options"),
representing approximately 2.5 per cent. of the Company's issued
share capital as enlarged by the Fundraise. The grant of options
will be subject to shareholder approval at the general meeting and,
if approved, will be granted pursuant to the Company's Employee
Share EMI Option Scheme.
The EMI Option Scheme currently contains a limit on the number
of options that can be granted in a 10-year period of 10 per cent.
of the issued share capital at the time of grant. Including the
proposed grant of options to Tom Oakley mentioned above, a total of
9.97 per cent. of the Enlarged Share Capital will have been granted
under option in the last 10-year period, of which 2.26 per cent.
was issued in the period but subsequently lapsed or were exercised.
Accordingly, subject to shareholder approval at the General
Meeting, the Board intends to amend its EMI Option Scheme to
increase the number of options that can be granted during the
10-year period from 10 per cent. to 12.5 per cent of the Company's
issued share capital at the time of the grant.
9. General Meeting
A notice convening a General Meeting of the Company, to be held
at offices of Peterhouse Capital Limited at 80 Cheapside, London
EC2V 6EE at 1:00 p.m. on 29 August 2019 will be set out in the
Circular. At the General Meeting, the following Resolutions will be
proposed:
1. Resolution numbered 1 will be proposed as an ordinary
resolution to grant authority to the Directors to allot the
166,666,667 New Ordinary Shares and up to an aggregate nominal
value of GBP450,000 being equivalent to the nominal value of
approximately one-third of the Enlarged Share Capital (there being
no current intention to use this further authority); and
2. Resolution numbered 2 will be proposed as a special
resolution to dis-apply statutory pre-emption rights in respect of
the allotment of up to 166,666,667 New Ordinary Shares and up to a
further aggregate nominal value of GBP202,500, which is equivalent
to the nominal value approximately 15 per cent. of the Enlarged
Share Capital (there being no current intention to use this further
authority).
3. Resolution numbered 3 will be proposed as an ordinary
resolution to grant authority to the Directors to grant options
over ordinary shares equivalent to 2.5 per cent. of the Enlarged
Share Capital;
4. Resolution numbered 4 will be proposed as an ordinary
resolution to increase the number of options that can be granted
under the EMI Option Scheme in any 10-year period from 10 per cent.
to 12.5 per cent. of the issued share capital of the Company.
Resolutions 1, 3 and 4 will be proposed as an ordinary
resolutions and Resolution 2 as a special resolution.
10. Directors' Recommendation
The Board of Feedback considers the Placing and the Subscription
to be in the best interests of the Company and its shareholders as
a whole and therefore the Directors unanimously recommend that
shareholders vote in favour of the Resolutions as they intend to do
in respect of their own shareholdings of, in aggregate, 20,433,333
Ordinary Shares (representing approximately 5.47 per cent. of the
Company's existing issued share capital).
11. Total Voting Rights
On Admission, the issued share capital of the Company will
consist of 539,949,917 Ordinary Shares with one voting right each.
The Company does not hold any ordinary shares in treasury.
Therefore, the total number of ordinary shares and voting rights in
the Company will be 539,949,917. With effect from Admission, this
figure may be used by Shareholders in the Company as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.
EXPECTED TIMETABLE OF PRINCIPAL EVENTS
Circular posted to Shareholders On or around 13
August 2019
Latest time and date for receipt of Form 1:00 p.m. on 27
of Proxy August 2019
General Meeting 1:00 p.m. on 29
August 2019
Admission and commencement of dealings 8:00 a.m. on 30
in the New Ordinary Shares to trading on August 2019
AIM
CREST member accounts expected to be credited 30 August 2019
for the New Ordinary Shares in uncertificated
form (where applicable)
Dispatch of definitive share certificates by 13 September
for the New Ordinary Shares in certificated 2019
form (where applicable)
PLACING AND SUBSCRIPTION STATISTICS
Issue Price 1.2 pence
Number of Existing Ordinary Shares 373,283,250
Total number of New Ordinary Shares 166,666,667
Total number of Ordinary Shares in issue
on Admission 539,949,917
Percentage of the Enlarged Share Capital 30.87 per cent.
represented by the New Ordinary Shares
Estimated net proceeds of the Placing and Approximately GBP1.9
Subscription million
ISIN GB0003340550
SEDOL 0334055
DEFINITIONS
Admission the admission of the New Ordinary Shares
to trading on AIM becoming effective
in accordance with the AIM Rules.
AIM AIM, a market operated by the London
Stock Exchange.
AIM Rules the AIM Rules for Companies, as published
and amended from time to time by the
London Stock Exchange.
Allenby Capital Allenby Capital Limited, the Company's
nominated adviser pursuant to the AIM
Rules.
Articles the existing articles of association
of the Company as at the date of this
announcement.
Brokers Peterhouse and Stanford Capital.
Circular the circular to be sent to shareholders
on or around 13 August 2019.
Company or Feedback Feedback plc.
CREST the computerised settlement system (as
defined in the CREST Regulations) which
facilitates the transfer of title to
shares in uncertificated form.
CREST Manual the manual, as amended from time to
time, produced by Euroclear UK & Ireland
which facilitates the transfer of shares
in uncertificated form.
CREST member a person who has been admitted by Euroclear
UK and Ireland as a system-member (as
defined in the CREST Regulations).
CREST Regulations the Uncertificated Securities Regulations
2001 (SI 2001/3755) (as amended).
Directors or Board the directors of the Company.
EMI Option Scheme the Company's Enterprise Management
Incentive Option Scheme.
Enlarged Share Capital the 539,949,917 Ordinary Shares in issue
immediately following Admission.
Euroclear UK & Ireland Euroclear UK & Ireland Limited, the
operator of CREST.
Existing Ordinary Shares the 373,283,250 existing Ordinary Shares
in issue in the capital of the Company
as at the date of this announcement.
Form of Proxy the form of proxy for use in connection
with the General Meeting which will
accompany the Circular.
General Meeting or GM the general meeting of Shareholders
to be held at the offices of Peterhouse
Capital Limited at 80 Cheapside, London
EC2V 6EE at 1:00 p.m. on 29 August 2019.
HMRC HM Revenue & Customs.
Independent Directors Dr Alastair Riddell, Dr Tom Oakley,
Simon Sturge and Prof Timothy Irish,
being the Directors who are not participating
in the Placing or the Subscription.
ISIN International Securities Identification
Number.
Issue Price 1.2 pence per New Ordinary Share.
London Stock Exchange London Stock Exchange plc.
New Ordinary Shares together the Placing Shares and the
Subscription Shares.
Notice of General Meeting the notice of General Meeting to be
set out in the Circular.
Optionholders the holders of options to acquire Ordinary
Shares, offered or granted in accordance
with the share option scheme operated
by the Company.
Ordinary Shares the ordinary shares of 0.25 pence per
share in the capital of the Company.
Peterhouse Peterhouse Capital Limited, the Company's
joint broker, pursuant to the AIM Rules.
Placing the placing of the Placing Shares at
the Issue Price, as described in this
announcement.
Placing Agreement the conditional agreement dated 9 August
2019 between (1) the Company; (2) Peterhouse;
(3) Stanford Capital and (4) the Directors
relating to the Placing.
Placing Shares the 108,966,667 new Ordinary Shares,
which have been placed by Peterhouse
and Stanford Capital with institutional
and other investors.
Resolutions the resolutions numbered 1 and 2 to
be proposed at the General Meeting as
set out in the Notice of General Meeting.
Shareholder(s) holder(s) of Ordinary Shares.
Stanford Capital Stanford Capital Partners Limited, the
Company's joint broker, pursuant to
the AIM Rules.
Subscription the conditional subscription for the
Subscription Shares by certain investors.
Subscription Shares the 57,700,000 new Ordinary Shares which
have been subscribed pursuant to the
Subscription
UK the United Kingdom.
uncertificated or in recorded on the relevant register of
uncertificated form the share or security concerned as being
held in uncertificated form in CREST
and title to which may be transferred
by means of CREST.
Warrantholders the holders of warrants to acquire Ordinary
Shares.
GBP or pence the lawful currency of the UK.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Lindsay Melvin
-------------------------- ------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------
a) Position/status Chief Financial Officer
-------------------------- ------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Feedback plc
-------------------------- ------------------------------------------
b) LEI 213800UGOF2GT2U2RV90
-------------------------- ------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description of the Ordinary shares of 0.25p each in Feedback
financial instrument, plc
type of instrument
Identification code Identification code (ISIN) for Feedback
plc ordinary shares:
GB0003340550
-------------------------- ------------------------------------------
b) Nature of the transaction Subscription for shares
-------------------------- ------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1.2p 416,667
----------
-------------------------- ------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- ------------------------------------------
e) Date of the transaction 9 August 2019
-------------------------- ------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- ------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Prof Rory Shaw
-------------------------- ------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------
a) Position/status PDMR
-------------------------- ------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Feedback plc
-------------------------- ------------------------------------------
b) LEI 213800UGOF2GT2U2RV90
-------------------------- ------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description of the Ordinary shares of 0.25p each in Feedback
financial instrument, plc
type of instrument
Identification code Identification code (ISIN) for Feedback
plc ordinary shares:
GB0003340550
-------------------------- ------------------------------------------
b) Nature of the transaction Subscription for shares
-------------------------- ------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1.2p 4,166,667
----------
-------------------------- ------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- ------------------------------------------
e) Date of the transaction 9 August 2019
-------------------------- ------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- ------------------------------------------
Enquiries:
Feedback plc
Tom Oakley, CEO +44 (0)1954 718072
Lindsay Melvin, CFO IR@fbk.com
Allenby Capital Limited (Nominated Adviser)
David Worlidge / Asha Chotai +44 (0)20 3328 5656
Peterhouse Capital Limited (Joint Broker)
Lucy Williams / Duncan Vasey +44 (0)20 7469 0936
Stanford Capital Partners Limited (Joint
Broker)
Patrick Claridge / John Howes +44 20 3815 8880
Instinctif Partners +44 (0)20 7457 2020
Rozi Morris/ Deborah Bell/ Phillip Marriage feedbackplc@instinctif.com
About Feedback plc
Feedback plc (AIM: FDBK) is a specialist medical imaging
technology company providing innovative software and systems,
through its fully-owned trading subsidiary, Feedback Medical
Limited. Its products advance the work of radiologists, clinicians
and medical researchers by improving workflows and giving unique
insights into diseases, particularly cancer. Feedback Medical works
with customers globally from headquarters in the internationally
renowned scientific hub of Cambridge, UK. Its proprietary
technologies are TexRAD(R) , the quantitative texture analysis tool
and Cadran, a picture archiving communication system (PACS). For
more information, see www.fbkmed.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEGGUAWRUPBPGG
(END) Dow Jones Newswires
August 12, 2019 02:00 ET (06:00 GMT)
Feedback (LSE:FDBK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Feedback (LSE:FDBK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
